Multimodal Therapy for Mesothelioma

Multimodal therapy for mesothelioma is a treatment strategy that combines two or more distinct treatment modalities — typically surgery, chemotherapy, and radiation therapy, and increasingly immunotherapy — to achieve better outcomes than any single modality can provide alone. Because mesothelioma is a diffuse cancer that spreads along tissue surfaces rather than forming a compact mass, complete surgical removal is extremely challenging, and recurrence after surgery alone is common. Multimodal therapy addresses this by using each treatment modality to target cancer cells that the others may miss.¹

The National Comprehensive Cancer Network (NCCN) guidelines recommend a multimodal approach for mesothelioma patients who are candidates for surgery. The specific combination and sequence of treatments depend on the cancer type (pleural vs. peritoneal), stage, histological subtype (epithelioid, sarcomatoid, or biphasic), and the patient's overall health and performance status. Epithelioid mesothelioma responds best to multimodal treatment, while sarcomatoid disease is generally less responsive. Early-stage disease with no distant metastasis is the strongest indication for aggressive multimodal therapy.²

The classic trimodality approach for pleural mesothelioma involves neoadjuvant chemotherapy (given before surgery to shrink the tumor and assess response), followed by cytoreductive surgery (extrapleural pneumonectomy or pleurectomy/decortication), and then adjuvant radiation therapy (given after surgery to the hemithorax to kill remaining microscopic disease). More recently, this framework has evolved to incorporate immunotherapy — particularly checkpoint inhibitors like nivolumab and ipilimumab — either in the neoadjuvant setting, as maintenance therapy after surgery, or in combination with chemotherapy.³

Patient selection is critical. Multimodal therapy is physically demanding, and not all patients are able to tolerate the combined effects of surgery, chemotherapy, and radiation. Thorough evaluation by a multidisciplinary team — including thoracic surgeons, medical oncologists, radiation oncologists, and pulmonologists — is essential to determine whether a patient is likely to benefit from an aggressive multimodal approach or whether a less intensive palliative strategy is more appropriate.⁴

Multimodal therapy for mesothelioma can be structured in several ways depending on the treatment sequence and specific modalities used:¹

• Neoadjuvant chemotherapy → surgery → adjuvant radiation — The most established trimodality protocol. Chemotherapy (typically pemetrexed + cisplatin) is given for 3–4 cycles before surgery to reduce tumor volume. Surgery follows, and radiation therapy is administered post-operatively to the hemithorax. This sequence allows physicians to assess tumor response to chemotherapy before committing to major surgery
• Surgery → adjuvant chemotherapy ± radiation — Surgery is performed first, followed by chemotherapy and potentially radiation. This approach may be preferred when the tumor appears resectable without neoadjuvant treatment or when a definitive diagnosis requires surgical tissue
• Surgery + intraoperative heated chemotherapy (HIPEC/HITHOC) — For peritoneal mesothelioma, cytoreductive surgery combined with heated intraperitoneal chemotherapy (HIPEC) is a well-established multimodal approach. For pleural disease, heated intrathoracic chemotherapy (HITHOC) is under investigation
• Immunotherapy + chemotherapy ± surgery — Emerging protocols integrate checkpoint inhibitors (nivolumab + ipilimumab, or pembrolizumab) with chemotherapy, sometimes followed by surgical consolidation for patients who respond well. Clinical trials are actively evaluating the optimal integration of immunotherapy into multimodal regimens

Key Treatment Modalities

• Surgery — Pleurectomy/decortication (P/D) or extrapleural pneumonectomy (EPP) for pleural mesothelioma; cytoreductive surgery (CRS) for peritoneal mesothelioma
• Chemotherapy — Pemetrexed + cisplatin (or carboplatin) is the standard first-line regimen
• Radiation therapy — Intensity-modulated radiation therapy (IMRT) is the preferred technique, allowing targeted dose delivery while sparing critical structures
• Immunotherapy — Nivolumab + ipilimumab (CheckMate 743 regimen) or pembrolizumab, used alone or combined with chemotherapy

Comprehensive diagnostic workup is essential before multimodal therapy to ensure proper patient selection:²

• Histological confirmation — Tissue biopsy confirming mesothelioma type and subtype (epithelioid, sarcomatoid, biphasic) is required. Subtype significantly influences treatment decisions and prognosis
• Staging imaging — CT chest/abdomen, PET-CT, and in some cases MRI to determine tumor extent, nodal involvement, and distant metastasis
• Mediastinoscopy or EBUS — To evaluate mediastinal lymph node involvement, which affects surgical candidacy
• Pulmonary function testing — To assess whether the patient can tolerate lung-removing surgery (EPP) or lung-sparing surgery (P/D)
• Cardiac evaluation — Echocardiography and sometimes stress testing to ensure cardiac fitness for major surgery
• Performance status assessment — ECOG or Karnofsky performance status scoring to evaluate the patient's ability to tolerate intensive multimodal treatment

The multimodal treatment process for mesothelioma involves careful coordination between multiple specialists:³

• Multidisciplinary tumor board — The patient's case is reviewed by a team of specialists who collectively determine the optimal treatment plan. Mesothelioma expertise is essential, as general oncology teams may not be familiar with the unique challenges of this disease
• Neoadjuvant phase — If chemotherapy is given first, patients typically receive 3–4 cycles (approximately 9–12 weeks) of pemetrexed/cisplatin. Imaging is performed after 2–3 cycles to assess response. Good responders proceed to surgery; poor responders may be redirected to alternative treatments
• Surgical phase — Cytoreductive surgery is performed by an experienced thoracic surgeon at a high-volume mesothelioma center. Recovery from major surgery typically requires 4–8 weeks before adjuvant treatment can begin
• Adjuvant phase — Post-surgical radiation (hemithoracic IMRT) and/or additional chemotherapy or immunotherapy is administered to eliminate residual microscopic disease. The specific adjuvant regimen depends on the surgical findings and the patient's recovery
• Surveillance — Regular follow-up imaging (CT scans every 3–6 months) to monitor for recurrence

Multimodal therapy offers the best chance of extended survival for eligible mesothelioma patients:⁴

• Median survival — Patients who complete multimodal therapy typically achieve median survival of 16–29 months, compared to 12–16 months with chemotherapy alone. Selected patients with epithelioid histology and complete macroscopic resection have achieved survival exceeding 3–5 years
• Histology matters — Epithelioid mesothelioma responds best to multimodal treatment. Sarcomatoid and biphasic subtypes have less favorable outcomes, and some protocols exclude sarcomatoid patients from aggressive surgical approaches
• Stage at treatment — Early-stage disease (stages I–II) treated with multimodal therapy has significantly better outcomes than advanced-stage disease
• Treatment center volume — Outcomes are substantially better at high-volume mesothelioma centers with experienced multidisciplinary teams. Patients should seek treatment at specialized centers whenever possible

Undergoing multimodal therapy is physically and emotionally demanding. Key considerations for patients:⁴

• Treatment duration — The complete multimodal process — from neoadjuvant chemotherapy through surgery and adjuvant treatment — typically spans 6 to 12 months. Planning for time away from work and arranging caregiver support is important
• Side effects management — Each treatment modality has its own side effects: chemotherapy (nausea, fatigue, low blood counts), surgery (pain, reduced lung function, recovery time), radiation (skin irritation, fatigue, esophagitis). The treatment team manages these proactively
• Nutrition and rehabilitation — Maintaining nutrition and physical conditioning throughout treatment improves tolerance and recovery. Pulmonary rehabilitation may be recommended after surgery
• Psychosocial support — The intensity of multimodal treatment can be overwhelming. Support groups, counseling, and social work services are important components of comprehensive care